Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 3/20 | 0.42 |
| ▸ | GABRD | O14764 | 3/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.42 |
| ▸ | GABRE | P78334 | 3/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.42 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.42 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.42 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL3339659 | 0.98 | GABRP (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1801333 | 0.85 | MAPT (0.41) | MAPTPGK1KMT2AHTT | |
| SCHEMBL476382 | 0.84 | PGK1 (0.38) | MAPTPGK1ALDH1A1KMT2AGAA | |
| SCHEMBL898592 | 0.82 | GABRP (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL11484236 | 0.81 | ACLY (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4882919 | 0.80 | KDM4D (0.41) | MAPTSMN1; SMN2KMT2AMEN1HTT | |
| Hydrochloric Acid SCHEMBL3055137 | 0.79 | CSNK2A1 (0.45) | MAPTGAA | |
| SCHEMBL486056 | 0.79 | MAPT (0.40) | MAPTSMN1; SMN2MAPK1PGK1KDM4E | |
| SCHEMBL10151931 | 0.78 | KDM4C (0.49) | MAPTKDM4E | |
| SCHEMBL23183169 | 0.78 | MAPT (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9675606-B2 | 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors | SANOFI (FR) | 2017-06-13 | — | — | US | disclosed |
| EP-2874625-B1 | USE OF VEGFR-3 INHIBITORS FOR TREATING HEPATOCELLULAR CARCINOMA | SANOFI SA (FR) | 2017-05-17 | — | — | EP | disclosed |
| EP-2903965-B1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | ORION CORP (FI) | 2017-03-01 | — | — | EP | disclosed |
| US-9533952-B2 | N-prop-2-ynyl carboxamide derivatives and their use as TRPA1 antagonists | ORION CORPORATION (FI) | 2017-01-03 | — | — | US | disclosed |
| CN-104602691-B | VEGFR 3 inhibitor is for treating the purposes of hepatocarcinoma | 赛诺菲 | 2016-12-28 | — | — | CN | disclosed |
| CN-103687852-B | 2-amino-3-(imidazoles-2-base)-pyridin-4-one derivatives and the purposes as vegf receptor kinase inhibitor thereof | 赛诺菲 | 2016-08-17 | — | — | CN | disclosed |
| US-9376432-B2 | Use of VEGFR-3 inhibitors for treating hepatocellular carcinoma | SANOFI (FR) | 2016-06-28 | — | — | US | disclosed |
| US-20150376130-A1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | Orlon Corporation (FI) | 2015-12-31 | — | — | US | disclosed |
| US-20150328205-A1 | 2-AMINO-3-(IMIDAZOL-2-YL)-PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR KINASE INHIBITORS | SANOFI (FR) | 2015-11-19 | — | — | US | disclosed |
| US-9126972-B2 | 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors | SANOFI (FR) | 2015-09-08 | — | — | US | disclosed |
| US-20120053170-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | SANOFI (FR) | 2012-03-01 | — | — | US | disclosed |
| US-20110124643-A1 | PYRIDINOPYRIDINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-05-26 | — | — | US | disclosed |
| EP-2315767-A2 | PYRIDINO-PYRIDINONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2011-05-04 | — | — | EP | disclosed |
| WO-2010109123-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010109115-A1 | ANTICANCER COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010109122-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | disclosed |
| CN-101808996-A | Nicotinamide derivatives, their preparation and their use in therapeutics | SANOFI AVENTIS | 2010-08-18 | — | — | CN | disclosed |
| US-20100144782-A1 | DERIVATIVES OF 7-ALKYNYL-1,8-NAPHTHYRIDONES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
| WO-2010004197-A2 | PYRIDINO-PYRIDINONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328205-A1 | 2-AMINO-3-(IMIDAZOL-2-YL)-PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR KINASE INHIBITORS | KDR, FLT4, FLT1 | GABRP 323/4885GABRD 1839/4885GABRA1 1015/4885 |
| US-20150376130-A1 | N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | GABRP 355/4885GABRD 913/4885GABRA1 385/4885 |
| US-20120053170-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | NAMPT, NNT, NQO1 | GABRP 3433/4885GABRD 4671/4885GABRA1 3857/4885 |
| US-20110124643-A1 | PYRIDINOPYRIDINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | FLT3, PDGFRB, PDGFRA | GABRP 282/4885GABRD 1019/4885GABRA1 779/4885 |
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | NNT, NAMPT, NQO1 | GABRP 2029/4885GABRD 3806/4885GABRA1 2387/4885 |
| US-20100144782-A1 | DERIVATIVES OF 7-ALKYNYL-1,8-NAPHTHYRIDONES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | ALK, ABL1, NTPCR | GABRP 4628/4885GABRD 4459/4885GABRA1 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.